347 related articles for article (PubMed ID: 16284877)
1. Oxalate degrading bacteria: new treatment option for patients with primary and secondary hyperoxaluria?
Hoppe B; von Unruh G; Laube N; Hesse A; Sidhu H
Urol Res; 2005 Nov; 33(5):372-5. PubMed ID: 16284877
[TBL] [Abstract][Full Text] [Related]
2. Association of intestinal oxalate-degrading bacteria with recurrent calcium kidney stone formation and hyperoxaluria: a case-control study.
Tavasoli S; Alebouyeh M; Naji M; Shakiba Majd G; Shabani Nashtaei M; Broumandnia N; Basiri A
BJU Int; 2020 Jan; 125(1):133-143. PubMed ID: 31145528
[TBL] [Abstract][Full Text] [Related]
3. Intestinal Oxalobacter formigenes colonization in calcium oxalate stone formers and its relation to urinary oxalate.
Troxel SA; Sidhu H; Kaul P; Low RK
J Endourol; 2003 Apr; 17(3):173-6. PubMed ID: 12803990
[TBL] [Abstract][Full Text] [Related]
4. Oxalate-degrading bacteria of the human gut as probiotics in the management of kidney stone disease.
Abratt VR; Reid SJ
Adv Appl Microbiol; 2010; 72():63-87. PubMed ID: 20602988
[TBL] [Abstract][Full Text] [Related]
5. A critical analysis of the role of gut Oxalobacter formigenes in oxalate stone disease.
Siva S; Barrack ER; Reddy GP; Thamilselvan V; Thamilselvan S; Menon M; Bhandari M
BJU Int; 2009 Jan; 103(1):18-21. PubMed ID: 19021605
[TBL] [Abstract][Full Text] [Related]
6. [Oxalobacter formigenes--characteristics and role in development of calcium oxalate urolithiasis].
Torzewska A
Postepy Hig Med Dosw (Online); 2013 Nov; 67():1144-53. PubMed ID: 24379255
[TBL] [Abstract][Full Text] [Related]
7. Hyperoxaluria, hypocitraturia, hypomagnesiuria, and lack of intestinal colonization by Oxalobacter formigenes in a cervical spinal cord injury patient with suprapubic cystostomy, short bowel, and nephrolithiasis.
Vaidyanathan S; von Unruh GE; Watson ID; Laube N; Willets S; Soni BL
ScientificWorldJournal; 2006 Apr; 6():2403-10. PubMed ID: 17619709
[TBL] [Abstract][Full Text] [Related]
8. Direct correlation between hyperoxaluria/oxalate stone disease and the absence of the gastrointestinal tract-dwelling bacterium Oxalobacter formigenes: possible prevention by gut recolonization or enzyme replacement therapy.
Sidhu H; Schmidt ME; Cornelius JG; Thamilselvan S; Khan SR; Hesse A; Peck AB
J Am Soc Nephrol; 1999 Nov; 10 Suppl 14():S334-40. PubMed ID: 10541258
[TBL] [Abstract][Full Text] [Related]
9. Oxalobacter formigenes produces metabolites and lipids undetectable in oxalotrophic Bifidobacterium animalis.
Chamberlain CA; Hatch M; Garrett TJ
Metabolomics; 2020 Nov; 16(12):122. PubMed ID: 33219444
[TBL] [Abstract][Full Text] [Related]
10. Stable expression of the oxc and frc genes from Oxalobacter formigenes in human embryo kidney 293 cells: implications for gene therapy of hyperoxaluria.
Ye ZQ; Kong DB; Chen ZQ; Yao LF; Guo H; Yu X; Liu GL; Yang WM
Int J Mol Med; 2007 Oct; 20(4):521-6. PubMed ID: 17786282
[TBL] [Abstract][Full Text] [Related]
11. Oxalobacter formigenes and its potential role in human health.
Duncan SH; Richardson AJ; Kaul P; Holmes RP; Allison MJ; Stewart CS
Appl Environ Microbiol; 2002 Aug; 68(8):3841-7. PubMed ID: 12147479
[TBL] [Abstract][Full Text] [Related]
12. In vitro anti-inflammatory activity of selected oxalate-degrading probiotic bacteria: potential applications in the prevention and treatment of hyperoxaluria.
Giardina S; Scilironi C; Michelotti A; Samuele A; Borella F; Daglia M; Marzatico F
J Food Sci; 2014 Mar; 79(3):M384-90. PubMed ID: 24471378
[TBL] [Abstract][Full Text] [Related]
13. Screening of different probiotic strains for their in vitro ability to metabolise oxalates: any prospective use in humans?
Mogna L; Pane M; Nicola S; Raiteri E
J Clin Gastroenterol; 2014; 48 Suppl 1():S91-5. PubMed ID: 25291139
[TBL] [Abstract][Full Text] [Related]
14. Reduction of oxaluria after an oral course of lactic acid bacteria at high concentration.
Campieri C; Campieri M; Bertuzzi V; Swennen E; Matteuzzi D; Stefoni S; Pirovano F; Centi C; Ulisse S; Famularo G; De Simone C
Kidney Int; 2001 Sep; 60(3):1097-105. PubMed ID: 11532105
[TBL] [Abstract][Full Text] [Related]
15. Oxalobacter sp. reduces urinary oxalate excretion by promoting enteric oxalate secretion.
Hatch M; Cornelius J; Allison M; Sidhu H; Peck A; Freel RW
Kidney Int; 2006 Feb; 69(4):691-8. PubMed ID: 16518326
[TBL] [Abstract][Full Text] [Related]
16. Bifidobacterium animalis subsp. lactis decreases urinary oxalate excretion in a mouse model of primary hyperoxaluria.
Klimesova K; Whittamore JM; Hatch M
Urolithiasis; 2015 Apr; 43(2):107-17. PubMed ID: 25269440
[TBL] [Abstract][Full Text] [Related]
17. A randomised Phase I/II trial to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria.
Hoppe B; Niaudet P; Salomon R; Harambat J; Hulton SA; Van't Hoff W; Moochhala SH; Deschênes G; Lindner E; Sjögren A; Cochat P
Pediatr Nephrol; 2017 May; 32(5):781-790. PubMed ID: 27924398
[TBL] [Abstract][Full Text] [Related]
18. The management of patients with enteric hyperoxaluria.
Asplin JR
Urolithiasis; 2016 Feb; 44(1):33-43. PubMed ID: 26645872
[TBL] [Abstract][Full Text] [Related]
19. Reduction of plasma oxalate levels by oral application of Oxalobacter formigenes in 2 patients with infantile oxalosis.
Hoppe B; Dittlich K; Fehrenbach H; Plum G; Beck BB
Am J Kidney Dis; 2011 Sep; 58(3):453-5. PubMed ID: 21705122
[TBL] [Abstract][Full Text] [Related]
20. Enteric oxalate elimination is induced and oxalate is normalized in a mouse model of primary hyperoxaluria following intestinal colonization with Oxalobacter.
Hatch M; Gjymishka A; Salido EC; Allison MJ; Freel RW
Am J Physiol Gastrointest Liver Physiol; 2011 Mar; 300(3):G461-9. PubMed ID: 21163900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
